Outcomes of selected SLE patients with aggressive immunosuppression close to PH onset.
Variables | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
---|---|---|---|---|---|---|---|
Admission age, yrs | 34.1 | 57.8 | 34.3 | 43.7 | 33.2 | 27.4 | 33.2 |
Sex | F | F | F | F | F | F | F |
SLEDAI-2K | 11 | 3 | 21 | 20 | 21 | 20 | 7 |
Aggressive immunosuppression | |||||||
Pulse MP, days before PH | − | − | − | +, 13 | − | +, 3 | +, 28 |
RTX, days before PH | − | +, 68 | − | +, 140 | − | − | − |
Pulse MP, days after PH | +, 11 | − | +, 9 | +, 0 | +, 6 | − | − |
Intensive care | + | + | + | + | + | + | − |
ETT+MV/ECMO | +/− | +/− | +/− | +/+ | +/− | +/− | −/− |
APACHE II | 27 | 32 | 24 | 26 | 24 | 26 | NA |
SOFA | 12 | 13 | 8 | 9 | 6 | 11 | NA |
Pathogens in BALF | |||||||
CMV/PJP | +/− | +/+ | +/+ | − | +/− | − | − |
Bacteria | SM, AB | − | − | − | − | − | − |
Bloodstream infection | SM | SM, AB | CMV | BC, CA | − | − | − |
90-day mortality | + | + | + | − | − | − | − |
180-day mortality | + | + | + | + | − | − | − |
SLE: systemic lupus erythematosus; AB: Acinetobacter baumanii; APACHE II: Acute Physiology and Chronic Health Evaluation II; BALF: bronchoalveolar lavage fluid: BC: Bacillus cereus; CA: Candida albicans; CMV: cytomegalovirus pneumonia; ECMO: extracorporeal membrane oxygenation; ETT+MV: endotracheal intubation + mechanical ventilation; NA: not applicable; MP: methylprednisolone; PH: pulmonary hemorrhage; PJP: Pneumocystic jiroveci pneumonia; RTX: rituximab; SLEDAI-2K: SLE Disease Activity Index 2000; SM: Stenotrophomonas maltophilia; SOFA: sequential organ failure assessment.